Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros










Base de dados
Assunto principal
Intervalo de ano de publicação
1.
Bioorg Med Chem Lett ; 79: 129083, 2023 01 01.
Artigo em Inglês | MEDLINE | ID: mdl-36414177

RESUMO

TYK2, a member of the JAK family of proximal membrane-bound tyrosine kinases, has emerged as an attractive target for the treatment of autoimmune diseases. Herein, we report the discovery of first-in-class potent and subtype-selective TYK2 degraders. By conjugating a TYK2 ligand from a known allosteric TYK2 inhibitor with a VHL ligand as the E3 ligase ligand via alkyl linkers of various lengths, we rapidly identified TYK2 degrader 5 with moderate TYK2 degradation activity. Degrader 5 induced TYK2 degradation without affecting the protein level of subtype kinases (JAK1, JAK2, and JAK3) in Jurkat cellular assays. Furthermore, modifying the TYK2 ligand moiety of degrader 5 yielded the more potent TYK2 degrader 37 with retained selectivity for JAKs. Our subtype-selective TYK2 degraders represent valuable chemical probes for investigating the biology of TYK2 degradation.


Assuntos
TYK2 Quinase , Humanos , Doenças Autoimunes/tratamento farmacológico , Janus Quinases/antagonistas & inibidores , Ligantes , Fosforilação , Processamento de Proteína Pós-Traducional , TYK2 Quinase/antagonistas & inibidores , /farmacologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...